Skip to content
Open access

Real-world effectiveness and safety of Ocrelizumab in a gulf multiple sclerosis cohort: extension of the Q-OCRE study to 451 patients.

Oct 2026 · Multiple Sclerosis and Related Disorders · Vol 115, pp. 107971 · 0 citations · 25 references
Medicine

Abstract

Real-world evidence on ocrelizumab in multiple sclerosis (MS) from the Middle East and North Africa (MENA) is limited. We extended our original Q-OCRE cohort (n = 60) to evaluate effectiveness and safety in an ethnically diverse Gulf population. In a single-center retrospective cohort of all patients starting ocrelizumab at Hamad General Hospital, Doha, Qatar (October 2017-May 2025), the primary outcome was No Evidence of Disease Activity (NEDA-3) at Year 1; secondary outcomes were annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) trajectory, 24-week confirmed disability worsening (CDW), persistence, and safety. A total of 451 patients were included (86.7% RRMS, 7.1% SPMS, 6.2% PPMS; 57.6% female; mean age 34.3 years; median follow-up 18.1 months; 696 person-years). The cohort was mildly affected at initiation (median EDSS 1.0; 42% with no relapse in the prior 2 years). ARR fell from 0.381 to 0.046, an 87% reduction (IRR 0.13, 95% CI 0.07-0.22, p < 0.001), preserved in patients meeting trial-like activity criteria (IRR 0.09). The EDSS slope was -0.04 points/year (p = 0.03) with a phenotype-by-time interaction (p < 0.001): RRMS improved while progressive forms worsened. NEDA-3 was 59.0% at Year 1 and 61.7% at Year 2. 24-week CDW reached 8.9% at 36 months, progressive phenotype being the only independent predictor (HR 5.02). Persistence was 90.7% at 36 months. Infusion-related reactions occurred in 18.4%, adjudicated opportunistic infections in 1.0%, IgG below 7 g/L in 6.9%, and incident malignancy in 0.4%, with no deaths and no progressive multifocal leukoencephalopathy. Ocrelizumab showed robust effectiveness and a favorable safety profile in this Gulf cohort, with disability trajectories dissociating by phenotype.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.